Table 2.

Top 40 medications by trigger volume with subsequent actions

Rank	Study medication	% of Triggered meds (site 1) a	% of Triggered meds (site 2)	% Problem yield (site 1)	% Abandoned (site 1)	% Not applicable selected (site 1)
1	Atorvastatin	9.55	4.99	89.5	8.39	2.15
2	Ondansetron	8.41	n/a	87.9	9.67	2.45
3	Senna	8.09	n/a	89.1	7.95	2.98
4	Lorazepam	7.84	4.47	76.0	12.17	11.81
5	Metoprolol	6.60	3.51	76.6	13.45	9.98
6	Docusate	6.33	n/a	86.7	10.85	2.45
7	Levothyroxine	6.11	1.94	89.3	9.62	1.07
8	Amlodipine	5.94	2.31	89.9	8.60	1.48
9	Insulin glargine	3.60	0.66	85.4	9.72	4.84
10	Furosemide	2.53	2.36	80.2	12.16	7.67
11	Losartan	2.50	1.80	85.4	13.27	1.31
12	Lisinopril	2.24	2.22	84.6	13.76	1.69
13	Rosuvastatin	2.20	2.06	89.7	8.93	1.42
14	Labetalol	1.75	0.99	78.4	10.55	11.10
15	Escitalopram	1.73	n/a	85.1	9.70	5.20
16	Sertraline	1.67	n/a	84.7	10.38	4.88
17	Hydrochlorothiazide	1.64	0.84	89.5	8.74	1.72
18	Budesonide/formoterol	1.60	1.00	80.8	14.88	4.31
19	Carvedilol	1.33	0.32	87.8	9.82	2.40
20	Nifedipine	1.19	0.73	78.5	11.27	10.21
21	Montelukast	1.15	2.06	84.0	9.70	6.34
22	Metformin	0.93	2.53	76.4	18.14	5.46
23	Metolazone	0.91	0.05	57.5	14.02	28.52
24	Fluoxetine	0.81	n/a	76.9	12.34	10.77
25	Budesonide inhalation	0.80	n/a	53.1	19.13	27.76
26	Spironolactone	0.77	1.23	79.9	14.49	5.57
27	Pravastatin	0.77	0.36	89.6	8.54	1.84
28	Diltiazem	0.74	0.16	76.8	19.48	3.70
29	Propranolol	0.71	n/a	36.4	15.56	48.05
30	Atenolol	0.65	0.23	80.9	11.83	7.23
31	Simvastatin	0.58	0.13	86.8	11.18	2.03
32	Citalopram	0.53	n/a	81.8	12.62	5.61
33	Tiotropium	0.46	0.13	81.2	15.78	3.06
34	Enalapril	0.43	n/a	81.0	16.03	2.93
35	Paroxetine	0.33	n/a	83.6	10.25	6.15
36	Alendronate	0.32	n/a	84.8	12.18	3.04
37	Doxazosin	0.27	0.10	77.6	8.01	14.36
38	Ezetimibe	0.27	0.16	90.5	8.08	1.39
39	Insulin nph	0.25	n/a	56.6	32.74	10.62
40	Chlorthalidone	0.24	0.23	86.4	12.38	1.24

Abbreviation: n/a: not applicable.

^aRanked in order of percentage of orders triggered at site 1 given the longer time period and greater n. Problem yield and abandonment rate by medication type was not available at site 2 at time of submission.